20/20 Biolabs, Inc.
AIDX
$1.46
$0.096.33%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.05M | 2.04M | 1.99M | 1.87M | 1.75M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.05M | 2.04M | 1.99M | 1.87M | 1.75M |
| Cost of Revenue | 1.44M | 1.41M | 1.47M | 1.43M | 1.39M |
| Gross Profit | 604.50K | 637.10K | 516.10K | 438.20K | 360.30K |
| SG&A Expenses | 3.34M | 3.39M | 4.19M | 4.48M | 4.76M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.38M | 5.71M | 6.74M | 7.08M | 7.41M |
| Operating Income | -3.33M | -3.66M | -4.75M | -5.21M | -5.66M |
| Income Before Tax | -3.74M | -3.68M | -4.73M | -5.14M | -5.55M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.74 | -3.68 | -4.73 | -5.14 | -5.55 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.74M | -3.68M | -4.73M | -5.14M | -5.55M |
| EBIT | -3.33M | -3.66M | -4.75M | -5.21M | -5.66M |
| EBITDA | -3.25M | -3.56M | -4.64M | -5.08M | -5.52M |
| EPS Basic | -0.75 | -0.76 | -0.98 | -1.07 | -1.16 |
| Normalized Basic EPS | -0.47 | -0.47 | -0.61 | -0.67 | -0.72 |
| EPS Diluted | -0.76 | -0.76 | -0.98 | -1.07 | -1.16 |
| Normalized Diluted EPS | -0.47 | -0.47 | -0.61 | -0.67 | -0.72 |
| Average Basic Shares Outstanding | 19.72M | 19.37M | 19.29M | 19.25M | 19.20M |
| Average Diluted Shares Outstanding | 19.72M | 19.37M | 19.29M | 19.25M | 19.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |